Drugs / 9MW3011
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06772766 | Dec 2024 → Oct 2026 expected | beta thalassemia | Mabwell (Shanghai) Bioscience Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06752746 | Mar 2024 → Aug 2025 overdue | acquired polycythemia vera | Mabwell (Shanghai) Bioscience Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06389942 | Mar 2023 → May 2024 | — | Mabwell (Shanghai) Bioscience Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 9MW3011 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06752746 ↗ |
| Route | Intravenous | “single ascending intravenous (IV) doses of 9MW3011” NCT06389942 ↗ |